- Home
- AKBA vs SWIM Comparison
AKBA vs SWIM Comparison
Compare AKBA & SWIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- SWIM
- Stock Information
- Founded
- AKBA 2007
- SWIM 1956
- Country
- AKBA United States
- SWIM United States
- Employees
- AKBA N/A
- SWIM N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- SWIM Plastic Products
- Sector
- AKBA Health Care
- SWIM Industrials
- Exchange
- AKBA Nasdaq
- SWIM Nasdaq
- Market Cap
- AKBA 729.1M
- SWIM 867.1M
- IPO Year
- AKBA 2014
- SWIM 2021
- Fundamental
- Price
- AKBA $3.09
- SWIM $7.49
- Analyst Decision
- AKBA Strong Buy
- SWIM Hold
- Analyst Count
- AKBA 5
- SWIM 3
- Target Price
- AKBA $6.90
- SWIM $6.93
- AVG Volume (30 Days)
- AKBA 2.6M
- SWIM 427.8K
- Earning Date
- AKBA 11-06-2025
- SWIM 11-04-2025
- Dividend Yield
- AKBA N/A
- SWIM N/A
- EPS Growth
- AKBA N/A
- SWIM N/A
- EPS
- AKBA N/A
- SWIM N/A
- Revenue
- AKBA $203,733,000.00
- SWIM $521,828,000.00
- Revenue This Year
- AKBA $43.91
- SWIM $9.17
- Revenue Next Year
- AKBA $32.09
- SWIM $5.38
- P/E Ratio
- AKBA N/A
- SWIM N/A
- Revenue Growth
- AKBA 16.75
- SWIM N/A
- 52 Week Low
- AKBA $1.52
- SWIM $4.56
- 52 Week High
- AKBA $4.08
- SWIM $8.46
- Technical
- Relative Strength Index (RSI)
- AKBA 59.78
- SWIM 50.49
- Support Level
- AKBA $2.93
- SWIM $7.29
- Resistance Level
- AKBA $3.19
- SWIM $8.11
- Average True Range (ATR)
- AKBA 0.13
- SWIM 0.33
- MACD
- AKBA 0.04
- SWIM 0.03
- Stochastic Oscillator
- AKBA 91.92
- SWIM 65.33
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.